Emmanuelle Pourcher1,2, Philippe Huot3,4. 1. Clinique Sainte-Anne Mémoire et Mouvement Faculty of Medicine Laval University Quebec City Quebec Canada. 2. Centre Thématique de Recherche en Neuroscience Laval University Quebec City Quebec Canada. 3. Department of Pharmacology Faculty of Medicine University of Montreal Montreal Quebec Canada. 4. Division of Neurology Centre Hospitalier de l'Université de Montréal Montreal Quebec Canada.
Abstract
BACKGROUND: Treatment of motor fluctuations in Parkinson's disease (PD) remains an unmet challenge. Adenosine 2A (A2A) receptors are located along the indirect pathway and represent a potential target to enhance l-3,4-dihydroxyphenylalanine (l-DOPA) antiparkinsonian action. METHODS: This article summarizes the preclinical and clinical literature on A2A antagonists in PD, with a specific focus on their effect on off time, on time, and dyskinesia. FINDINGS: Several A2A receptor antagonists have been tested in preclinical studies and clinical trials. In preclinical studies, A2A antagonists enhanced l-DOPA antiparkinsonian action without exacerbating dyskinesia, but A2A antagonists were generally administered in combination with a subthreshold dose of l-DOPA, which is different to the paradigms used in clinical trials, where A2A antagonists were usually added to an optimal antiparkinsonian regimen. In clinical settings, A2A antagonists generally reduced duration of off time, by as much as 25% in some studies. The effect of on time duration is less clear, and in a few studies an exacerbation of dyskinesia was reported. Two A2A antagonists have been tested in phase III settings: istradefylline and preladenant. Istradefylline was effective in two phase III trials, but ineffective in another; the drug has been commercially available in Japan since 2013. In contrast, preladenant was ineffective in a phase III trial and the drug was discontinued. A phase III study with tozadenant will begin in 2015; the drug was effective at reducing off time in a phase IIb study. Other A2A antagonists are in development at the preclinical and early clinical levels.
BACKGROUND: Treatment of motor fluctuations in Parkinson's disease (PD) remains an unmet challenge. Adenosine 2A (A2A) receptors are located along the indirect pathway and represent a potential target to enhance l-3,4-dihydroxyphenylalanine (l-DOPA) antiparkinsonian action. METHODS: This article summarizes the preclinical and clinical literature on A2A antagonists in PD, with a specific focus on their effect on off time, on time, and dyskinesia. FINDINGS: Several A2A receptor antagonists have been tested in preclinical studies and clinical trials. In preclinical studies, A2A antagonists enhanced l-DOPA antiparkinsonian action without exacerbating dyskinesia, but A2A antagonists were generally administered in combination with a subthreshold dose of l-DOPA, which is different to the paradigms used in clinical trials, where A2A antagonists were usually added to an optimal antiparkinsonian regimen. In clinical settings, A2A antagonists generally reduced duration of off time, by as much as 25% in some studies. The effect of on time duration is less clear, and in a few studies an exacerbation of dyskinesia was reported. Two A2A antagonists have been tested in phase III settings: istradefylline and preladenant. Istradefylline was effective in two phase III trials, but ineffective in another; the drug has been commercially available in Japan since 2013. In contrast, preladenant was ineffective in a phase III trial and the drug was discontinued. A phase III study with tozadenant will begin in 2015; the drug was effective at reducing off time in a phase IIb study. Other A2A antagonists are in development at the preclinical and early clinical levels.
Entities:
Keywords:
A2A receptor; Parkinson's disease; dyskinesia; off time; on time
Authors: Roger J Gillespie; Samantha J Bamford; Ruth Botting; Mike Comer; Sarah Denny; Suneel Gaur; Michael Griffin; Allan M Jordan; Anthony R Knight; Joanne Lerpiniere; Stefania Leonardi; Sean Lightowler; Steven McAteer; Angela Merrett; Anil Misra; Antony Padfield; Mark Reece; Mona Saadi; Daniel L Selwood; Gemma C Stratton; Dominic Surry; Richard Todd; Xin Tong; Vicki Ruston; Rebecca Upton; Scott M Weiss Journal: J Med Chem Date: 2009-01-08 Impact factor: 7.446
Authors: Stewart A Factor; Kenneth Wolski; Daniel M Togasaki; Susan Huyck; Marc Cantillon; T W Ho; Robert A Hauser; Emmanuelle Pourcher Journal: Mov Disord Date: 2013-04-15 Impact factor: 10.338
Authors: Liqun Yu; Hai-Ying Shen; Joana E Coelho; Inês M Araújo; Qing-Yuan Huang; Yuan-Ji Day; Nelson Rebola; Paula M Canas; Erica Kirsten Rapp; Jarrod Ferrara; Darcie Taylor; Christa E Müller; Joel Linden; Rodrigo A Cunha; Jiang-Fan Chen Journal: Ann Neurol Date: 2008-03 Impact factor: 10.422
Authors: Amnon A Berger; Ariel Winnick; Alexandra Welschmeyer; Alicia Kaneb; Kevin Berardino; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits Journal: Neurol Int Date: 2020-12-08